HSPG2 (heparan sulfate proteoglycan 2)

Gene

• Entrez ID: 3339
• Gene name: Heparan sulfate proteoglycan 2
• Gene symbol: HSPG2
• Synonyms: HSPG, PLC, PRCAN, SJA, SJS, SJS1
• Chromosome: 1
• Chromosome location: 1p36.12
• Summary: This gene encodes the perlecan protein, which consists of a core protein to which three long chains of glycosaminoglycans (heparan sulfate or chondroitin sulfate) are attached. The perlecan protein is a large multidomain proteoglycan that binds to and cross-links many extracellular matrix components and cell-surface molecules. It has been shown that this protein interacts with laminin, prolargin, collagen type IV, FGFBP1, FBLN2, FGF7 and transthyretin, etc., and it plays essential roles in multiple biological activities. Perlecan is a key component of the vascular extracellular matrix, where it helps to maintain the endothelial barrier function. It is a potent inhibitor of smooth muscle cell proliferation and is thus thought to help maintain vascular homeostasis. It can also promote growth factor (e.g., FGF2) activity and thus stimulate endothelial growth and re-generation. It is a major component of basement membranes, where it is involved in the stabilization of other molecules as well as being involved with glomerular permeability to macromolecules and cell adhesion. Mutations in this gene cause Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]

SNPs

SNP ID	Visualize variation	Clinical significance	Consequence
rs2229490	C>A,T	Conflicting-interpretations-of-pathogenicity	Coding sequence variant, missense variant
rs55875654	G>A	Uncertain-significance, conflicting-interpretations-of-pathogenicity, likely-benign	Coding sequence variant, synonymous variant
rs62642527	C>T	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs62642535	T>A,G	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs111866498	G>A	Uncertain-significance, benign, conflicting-interpretations-of-pathogenicity	Synonymous variant, coding sequence variant
rs113652076	G>A,C,T	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs137853248	C>T	Pathogenic	Missense variant, coding sequence variant
rs138518139	T>A,C	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs139794766	G>A	Conflicting-interpretations-of-pathogenicity, uncertain-significance, likely-benign	Missense variant, coding sequence variant
rs139838884	C>G	Conflicting-interpretations-of-pathogenicity, uncertain-significance	Missense variant, coding sequence variant
rs139842104	T>C	Conflicting-interpretations-of-pathogenicity	Synonymous variant, coding sequence variant
rs142433309	G>A	Conflicting-interpretations-of-pathogenicity, benign	Coding sequence variant, missense variant
rs142736845	G>A,C	Conflicting-interpretations-of-pathogenicity, uncertain-significance	Coding sequence variant, missense variant
rs143109401	C>T	Conflicting-interpretations-of-pathogenicity, uncertain-significance	Coding sequence variant, missense variant
rs143437991	G>A,C	Conflicting-interpretations-of-pathogenicity, uncertain-significance	Coding sequence variant, missense variant
rs143669458	C>T	Conflicting-interpretations-of-pathogenicity, uncertain-significance	Coding sequence variant, missense variant
rs147286334	C>T	Uncertain-significance, conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs149159881	G>A	Uncertain-significance, benign, conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs150129885	A>G,T	Uncertain-significance, conflicting-interpretations-of-pathogenicity	Missense variant, synonymous variant, coding sequence variant
rs189837148	C>T	Conflicting-interpretations-of-pathogenicity	Coding sequence variant, synonymous variant
rs201491948	G>A	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs369899077	G>A	Uncertain-significance, conflicting-interpretations-of-pathogenicity	Coding sequence variant, synonymous variant
rs376929779	G>A	Conflicting-interpretations-of-pathogenicity	Synonymous variant, coding sequence variant
rs534949106	G>A	Conflicting-interpretations-of-pathogenicity	Synonymous variant, coding sequence variant
rs535956121	G>A	Conflicting-interpretations-of-pathogenicity	Missense variant, coding sequence variant
rs745452577	G>A	Uncertain-significance, likely-pathogenic	Synonymous variant, coding sequence variant
rs756733330	T>C	Conflicting-interpretations-of-pathogenicity	Intron variant
rs762281715	G>A	Pathogenic	Stop gained, coding sequence variant
rs763945561	G>-,GG	Likely-pathogenic	Frameshift variant, coding sequence variant
rs778653296	C>A,T	Pathogenic	Splice donor variant
rs868479224	C>A,T	Likely-pathogenic	Splice acceptor variant
rs886039909	C>T	Likely-pathogenic	Intron variant
rs886041667	GC>-	Pathogenic	Frameshift variant, coding sequence variant
rs886044168	T>C	Conflicting-interpretations-of-pathogenicity	Synonymous variant, coding sequence variant
rs927473035	C>A,T	Pathogenic	Splice donor variant
rs1064795546	C>T	Likely-pathogenic	Stop gained, coding sequence variant
rs1373848573	C>A	Likely-pathogenic	Splice donor variant
rs1572204991	T>C	Pathogenic	Intron variant
rs1572220282	T>C	Pathogenic	Intron variant
rs1572304438	AAAGTTGCCAAAAGAGAGC>-	Pathogenic	Coding sequence variant, frameshift variant
rs1572319254	TC>A	Pathogenic	Coding sequence variant, frameshift variant
rs1572356343	C>T	Likely-pathogenic	Intron variant

miRNA

miRTarBase ID	miRNA	Experiments	Reference
MIRT007259	hsa-miR-663a	Luciferase reporter assay	23436656
MIRT018272	hsa-miR-335-5p	Microarray	18185580
MIRT440478	hsa-miR-218-5p	HITS-CLIP	23212916
MIRT738672	hsa-miR-1972	PAR-CLIP	26701625
MIRT738672	hsa-miR-1972	PAR-CLIP	27292025
MIRT741424	hsa-miR-346	PAR-CLIP	26701625
MIRT743510	hsa-miR-4266	PAR-CLIP	26701625
MIRT743510	hsa-miR-4266	PAR-CLIP	27292025
MIRT743779	hsa-miR-4294	PAR-CLIP	26701625
MIRT744805	hsa-miR-4459	PAR-CLIP	26701625
MIRT744805	hsa-miR-4459	PAR-CLIP	27292025
MIRT746068	hsa-miR-4536-5p	PAR-CLIP	26701625
MIRT746068	hsa-miR-4536-5p	PAR-CLIP	27292025
MIRT746926	hsa-miR-4681	PAR-CLIP	26701625
MIRT746926	hsa-miR-4681	PAR-CLIP	27292025
MIRT747180	hsa-miR-4695-5p	PAR-CLIP	26701625
MIRT747180	hsa-miR-4695-5p	PAR-CLIP	27292025
MIRT747489	hsa-miR-4716-3p	PAR-CLIP	26701625
MIRT747653	hsa-miR-4723-5p	PAR-CLIP	26701625
MIRT747779	hsa-miR-4727-5p	PAR-CLIP	26701625
MIRT748645	hsa-miR-4769-3p	PAR-CLIP	26701625
MIRT748736	hsa-miR-4779	PAR-CLIP	26701625
MIRT748736	hsa-miR-4779	PAR-CLIP	27292025
MIRT751285	hsa-miR-5698	PAR-CLIP	26701625
MIRT753199	hsa-miR-6511b-5p	PAR-CLIP	26701625
MIRT753199	hsa-miR-6511b-5p	PAR-CLIP	27292025
MIRT753635	hsa-miR-665	PAR-CLIP	26701625
MIRT753635	hsa-miR-665	PAR-CLIP	27292025
MIRT756089	hsa-miR-6794-5p	PAR-CLIP	26701625
MIRT756686	hsa-miR-6811-5p	PAR-CLIP	26701625
MIRT756686	hsa-miR-6811-5p	PAR-CLIP	27292025
MIRT756831	hsa-miR-6817-5p	PAR-CLIP	26701625
MIRT757986	hsa-miR-6870-5p	PAR-CLIP	26701625
MIRT759043	hsa-miR-7111-5p	PAR-CLIP	26701625
MIRT759222	hsa-miR-7154-3p	PAR-CLIP	26701625
MIRT759222	hsa-miR-7154-3p	PAR-CLIP	27292025

Gene ontology (GO)

GO ID	Ontology	Definition	Evidence	Reference
GO:0001523	Process	Retinoid metabolic process	TAS
GO:0001525	Process	Angiogenesis	IEA
GO:0001540	Function	Amyloid-beta binding	IC	21289173
GO:0005509	Function	Calcium ion binding	IEA
GO:0005515	Function	Protein binding	IPI	11956183, 21596751, 23374253
GO:0005576	Component	Extracellular region	HDA	27068509
GO:0005576	Component	Extracellular region	TAS
GO:0005604	Component	Basement membrane	IBA	21873635
GO:0005604	Component	Basement membrane	TAS	8621634, 21126803
GO:0005615	Component	Extracellular space	HDA	16502470, 20551380
GO:0005796	Component	Golgi lumen	TAS
GO:0005886	Component	Plasma membrane	TAS
GO:0005925	Component	Focal adhesion	HDA	21423176
GO:0006024	Process	Glycosaminoglycan biosynthetic process	TAS
GO:0006027	Process	Glycosaminoglycan catabolic process	TAS
GO:0006629	Process	Lipid metabolic process	TAS	21289173
GO:0006898	Process	Receptor-mediated endocytosis	ISS
GO:0006954	Process	Inflammatory response	TAS	21126803
GO:0007420	Process	Brain development	TAS	21126803
GO:0008022	Function	Protein C-terminus binding	IPI	12604605
GO:0009887	Process	Animal organ morphogenesis	IBA	21873635
GO:0009888	Process	Tissue development	IBA	21873635
GO:0016525	Process	Negative regulation of angiogenesis	TAS	21126803
GO:0030021	Function	Extracellular matrix structural constituent conferring compression resistance	ISS
GO:0030021	Function	Extracellular matrix structural constituent conferring compression resistance	RCA	20551380, 23979707, 25037231, 27559042, 28327460, 28675934
GO:0030154	Process	Cell differentiation	TAS	21126803
GO:0030198	Process	Extracellular matrix organization	TAS
GO:0043202	Component	Lysosomal lumen	TAS
GO:0044267	Process	Cellular protein metabolic process	TAS
GO:0050750	Function	Low-density lipoprotein particle receptor binding	TAS	21289173
GO:0062023	Component	Collagen-containing extracellular matrix	HDA	23658023, 23979707, 25037231, 27559042, 28327460, 28675934
GO:0062023	Component	Collagen-containing extracellular matrix	HDA	20551380
GO:0062023	Component	Collagen-containing extracellular matrix	ISS	22261194
GO:0070062	Component	Extracellular exosome	HDA	19056867, 19199708, 21362503, 23533145
GO:0072359	Process	Circulatory system development	TAS	21126803
GO:0098797	Component	Plasma membrane protein complex	TAS	21289173

Other IDs

• MIM: 142461
• HGNC: 5273
• e!Ensembl: ENSG00000142798

Protein

• UniProt ID: P98160
• Protein name: Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) (Perlecan) (PLC) [Cleaved into: Endorepellin; LG3 peptide]
• Protein function: Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.; Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.; The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.
• PDB: 3SH4, 3SH5
• Family and domains:

  Pfam

  Accession	ID	Position in sequence	Description	Type
  PF00057	Ldl_recept_a	197 → 234	Low-density lipoprotein receptor domain class A	Repeat
  PF00057	Ldl_recept_a	283 → 319	Low-density lipoprotein receptor domain class A	Repeat
  PF00057	Ldl_recept_a	323 → 359	Low-density lipoprotein receptor domain class A	Repeat
  PF00057	Ldl_recept_a	366 → 403	Low-density lipoprotein receptor domain class A	Repeat
  PF13927	Ig_3	405 → 483		Domain
  PF00052	Laminin_B	595 → 729	Laminin B (Domain IV)	Family
  PF00053	Laminin_EGF	764 → 811	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	814 → 869	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	867 → 921	Laminin EGF domain	Domain
  PF00052	Laminin_B	990 → 1124	Laminin B (Domain IV)	Family
  PF00053	Laminin_EGF	1116 → 1156	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	1159 → 1206	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	1209 → 1264	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	1275 → 1322	Laminin EGF domain	Domain
  PF00052	Laminin_B	1396 → 1528	Laminin B (Domain IV)	Family
  PF00053	Laminin_EGF	1523 → 1556	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	1563 → 1610	Laminin EGF domain	Domain
  PF00053	Laminin_EGF	1613 → 1668	Laminin EGF domain	Domain
  PF13927	Ig_3	1676 → 1750		Domain
  PF13927	Ig_3	1769 → 1844		Domain
  PF07679	I-set	1866 → 1950	Immunoglobulin I-set domain	Domain
  PF07679	I-set	1956 → 2042	Immunoglobulin I-set domain	Domain
  PF13927	Ig_3	2050 → 2121		Domain
  PF13927	Ig_3	2153 → 2221		Domain
  PF13927	Ig_3	2245 → 2315		Domain
  PF13927	Ig_3	2342 → 2410		Domain
  PF07679	I-set	2437 → 2520	Immunoglobulin I-set domain	Domain
  PF13927	Ig_3	2535 → 2604		Domain
  PF13927	Ig_3	2629 → 2700		Domain
  PF13927	Ig_3	2728 → 2796		Domain
  PF07679	I-set	2827 → 2910	Immunoglobulin I-set domain	Domain
  PF13895	Ig_2	2926 → 3009	Immunoglobulin domain	Domain
  PF13927	Ig_3	3021 → 3095		Domain
  PF13927	Ig_3	3111 → 3189		Domain
  PF07679	I-set	3212 → 3295	Immunoglobulin I-set domain	Domain
  PF07679	I-set	3299 → 3382	Immunoglobulin I-set domain	Domain
  PF07679	I-set	3400 → 3483	Immunoglobulin I-set domain	Domain
  PF07679	I-set	3489 → 3572	Immunoglobulin I-set domain	Domain
  PF07679	I-set	3576 → 3658	Immunoglobulin I-set domain	Domain
  PF00054	Laminin_G_1	3692 → 3831	Laminin G domain	Domain
  PF00008	EGF	3848 → 3879	EGF-like domain	Domain
  PF00054	Laminin_G_1	3957 → 4088	Laminin G domain	Domain
  PF00008	EGF	4108 → 4139	EGF-like domain	Domain
  PF02210	Laminin_G_2	4234 → 4364	Laminin G domain	Domain

• Sequence:

  MGWRAAGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDML
  ADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLE
  SEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTS
  PQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLG
  ISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPR
  DYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCP
  TKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASR
  GQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCE
  AMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQI
  RLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPE
  QFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLMGAGYRLLSRGHTPTQPGALNQR
  QVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHAT
  SHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCNCNGHASSCDPVYGHC
  LNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCD
  ACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVG
  RLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAAS
  THTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPG
  STPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMA
  LAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDC
  DTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQR
  GTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQG
  QPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPD
  GCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGA
  QLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGN
  NIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSV
  PLAASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHC
  ELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNP
  ENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVE
  VHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSD
  AGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSP
  AYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQAS
  GTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRL
  PAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAA
  GVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQV
  VVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGS
  RLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSS
  SHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHV
  VGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYK
  RGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGST
  QPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPA
  DSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLV
  AGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTI
  QQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQI
  VGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPT
  VVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANN
  NIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTW
  HKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHV
  PAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRL
  NQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQ
  TLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPE
  QEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRN
  QELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEG
  PVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDA
  GTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPA
  PTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPY
  ATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDS
  GRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFH
  CAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQ
  LVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVV
  RIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASG
  YPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPE
  RVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQ
  PDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVN
  GTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAH
  GISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCV
  NRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPL
  APDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAER
  LNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEV
  SVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLC
  EHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPG
  QYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFI
  SLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSP
  GPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRA
  QAGANTRPCPS

• Sequence length: 4391